PharmaEngine, Inc. AI Stock Analysis
PharmaEngine, Inc. (4162) AI Stock Analysis
PharmaEngine, Inc.
(TPEx:4162)
The score is anchored by PharmaEngine's strong financial foundation: virtually no debt, NT$4.93 billion of equity, industry-leading margins and record free cash flow of roughly NT$1.73 billion. Valuation reinforces the case, with a P/E of 14.2, a 3.78% dividend yield and low beta. The main drags are earnings unpredictability — 2025 revenue and net income fell sharply from an exceptional 2024 as milestone income normalized — and a weak price trend, with shares trading below all major moving averages on negative MACD, though momentum indicators suggest the stock is nearing oversold levels.
PharmaEngine, Inc. (4162) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.59B
- Dividend Yield
- 3.79%
- Average Volume (3M)
- 275.90K
- Price to Earnings (P/E)
- 14.2
- Beta (1Y)
- 0.42
- Revenue Growth
- -58.69%
- EPS Growth
- -66.96%
- Country
- TW
- Employees
- 45
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
PharmaEngine, Inc. Business Overview & Revenue Model
Company Description
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irin...
PharmaEngine, Inc. Financial Statement Overview
Summary
PharmaEngine combines a near debt-free balance sheet (debt-to-equity under 0.01, equity funding ~96% of assets) with exceptional margins (gross margin consistently 92%-98%) and record free cash flow of about NT$1.73 billion in 2025. The offset is a highly volatile top line: fiscal 2025 revenue fell roughly 64% to NT$911 million and net income dropped from NT$1.75 billion to NT$388 million, with return on equity slipping from ~32% to ~8%. Earnings depend on milestone and royalty timing rather than a recurring commercial base, and the large equity cushion is underutilized outside of peak years.
Income Statement
62PositiveBalance Sheet
90Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.03B | 911.42M | 2.52B | 767.67M | 654.38M | 654.84M |
| Gross Profit | 959.62M | 849.51M | 2.48B | 718.97M | 604.68M | 617.76M |
| EBITDA | 635.99M | 519.48M | 2.17B | 347.31M | 401.15M | 555.87M |
| Net Income | 538.80M | 387.64M | 1.75B | 274.65M | 318.78M | 426.03M |
Balance Sheet | ||||||
| Total Assets | 5.42B | 5.15B | 5.85B | 3.95B | 3.97B | 4.03B |
| Cash, Cash Equivalents and Short-Term Investments | 5.07B | 4.72B | 3.86B | 3.63B | 3.66B | 3.81B |
| Total Debt | 37.78M | 42.12M | 7.14M | 14.81M | 22.35M | 7.59M |
| Total Liabilities | 512.25M | 221.59M | 448.01M | 91.01M | 94.47M | 87.70M |
| Stockholders Equity | 4.91B | 4.93B | 5.40B | 3.86B | 3.87B | 3.94B |
Cash Flow | ||||||
| Free Cash Flow | 540.31M | 1.73B | 455.32M | 256.56M | 198.07M | 929.44M |
| Operating Cash Flow | 540.65M | 1.73B | 456.73M | 256.97M | 202.01M | 929.67M |
| Investing Cash Flow | -1.26B | -266.65M | -115.54M | -855.48M | -188.12M | -107.00M |
| Financing Cash Flow | -870.61M | -870.37M | -223.11M | -294.73M | -395.71M | -507.00M |
PharmaEngine, Inc. Peers Comparison
Overall Rating
- TW:416270Outperform
TW:416954Neutral
TW:412844Neutral
TW:654143Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4162 | 70Outperform | TWD 7.43B | 14.16 | ― | 3.79% | -58.69% | -66.96% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4169 | 54Neutral | TWD 7.93B | -301.25 | ― | 0.27% | ― | ― |
| TW:4128 | 44Neutral | TWD 7.85B | 14.95 | ― | ― | 4.85% | ― |
| TW:6541 | 43Neutral | TWD 7.47B | -5.00 | -26.61% | ― | 492.43% | 21.57% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4162 | PharmaEngine, Inc. | 52.80 | -16.88 | -24.23% | |
| TW:6541 | Tanvex Biopharma | 28.15 | -27.55 | -49.46% | |
| TW:4128 | Microbio Co., Ltd. | 13.55 | -7.25 | -34.86% | |
| TW:4169 | TCM Biotech International Corp. | 120.50 | -60.77 | -33.52% | |
| TW:6976 | Acepodia, Inc. | 12.10 | -3.20 | -20.92% | |
| TW:7876 | Obigen Pharma, Inc. | 60.90 | 24.21 | 66.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026